Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00506441 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT00506441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00506441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-center, Withdrawal Study Comparing MCI-196 v.s Placebo Following A 12-Week Dose Titration Period With MCI-196 in Stage V Subjects on Dialysis With Hyperphosphatemia
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2007
Completion date
September 30, 2009
Enrollment
245 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, dialysis, hyperphosphatemia